Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 19/20 | 0.54 |
| ▸ | MMP9 | P14780 | 18/20 | 0.54 |
| ▸ | MMP3 | P08254 | 17/20 | 0.54 |
| ▸ | MMP7 | P09237 | 17/20 | 0.54 |
| ▸ | MMP13 | P45452 | 16/20 | 0.54 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL328472 | 1.00 | MMP1 (0.54) | MMP1MMP9MMP3MMP7MMP13 | |
| SCHEMBL919124 | 0.99 | MMP1 (0.53) | MMP1MMP9MMP3MMP7MMP13 | |
| SCHEMBL919122 | 0.99 | MMP1 (0.53) | MMP1MMP9MMP3MMP7MMP13 | |
| SCHEMBL779102 | 0.94 | MMP1 (0.55) | MMP1MMP9MMP3MMP7MMP13 | |
| SCHEMBL779193 | 0.93 | MMP1 (0.55) | MMP1MMP9MMP3MMP7MMP13 | |
| SCHEMBL779159 | 0.92 | MMP1 (0.57) | MMP1MMP9MMP3MMP7MMP13 | |
| SCHEMBL12942841 | 0.92 | MMP9 (0.44) | MMP1MMP9MMP3MMP7MMP13 | |
| SCHEMBL778946 | 0.91 | MMP1 (0.55) | MMP1MMP9MMP3MMP7MMP13 | |
| SCHEMBL14878435 | 0.90 | MMP9 (0.42) | MMP1MMP9MMP3MMP7MMP13 | |
| SCHEMBL12905327 | 0.89 | MMP9 (0.41) | MMP1MMP9MMP3MMP7MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023196958-A2 | TUMOR AND CANCER TARGETING COMPOUNDS | ONCOLINX PHARMACEUTICALS (US) | 2023-10-12 | — | — | WO | claimed |
| US-20260139061-A1 | TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRvIII CHIMERIC ANTIGEN RECEPTOR | NOVARTIS AG (CH) | 2026-05-21 | — | — | US | disclosed |
| US-12616733-B2 | XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12595260-B2 | Stable heavy isotopes in amide functional groups and uses thereof | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2026-04-07 | — | — | US | disclosed |
| EP-4714966-A2 | CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE | Cero Therapeutics Holdings, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260077015-A1 | CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF | CERO THERAPEUTICS HOLDINGS INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4376874-B1 | CHIMERIC TIM4 RECEPTORS AND USES THEREOF | CERO THERAPEUTICS HOLDINGS INC (US) | 2026-03-04 | — | — | EP | disclosed |
| US-12559562-B2 | Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor | NOVARTIS AG (CH) | 2026-02-24 | — | — | US | disclosed |
| EP-3688032-B1 | CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE | CERO THERAPEUTICS HOLDINGS INC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250250315-A1 | CHIMERIC TIM4 RECEPTORS AND USES THEREOF | CERO THERAPEUTICS HOLDINGS INC (US) | 2025-08-07 | — | — | US | disclosed |
| EP-4038097-A1 | CHIMERIC TIM4 RECEPTORS AND USES THEREOF | Cero Therapeutics, Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
| WO-2022123316-A1 | COMPOSITIONS OF GUANYLYL CYCLASE C (GCC) ANTIGEN BINDING AGENTS AND METHODS OF USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-06-16 | — | — | WO | disclosed |
| EP-4000619-A1 | DOSAGE REGIMEN FOR AN ALPHA-ISOFORM SELECTIVE PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR | Novartis AG (CH) | 2022-05-25 | — | — | EP | disclosed |
| WO-2022098907-A1 | METHODS AND COMPOSITIONS FOR TREATING FIBROTIC DISEASES | MAX BioPharma, Inc. (US) | 2022-05-12 | — | — | WO | disclosed |
| US-20220098273-A1 | CHIMERIC ENGULFMENT RECEPTOR MOLECULES | CERO THERAPEUTICS HOLDINGS, INC. | 2022-03-31 | — | — | US | disclosed |
| EP-3519441-B1 | CHIMERIC ENGULFMENT RECEPTOR MOLECULES | CERO THERAPEUTICS INC (US) | 2022-03-30 | — | — | EP | disclosed |
| WO-2022036285-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH CHIMERIC TIM RECEPTORS IN COMBINATION WITH INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE | CERO THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| WO-2022036287-A1 | ANTI-CD72 CHIMERIC RECEPTORS AND USES THEREOF | CERO THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| WO-2022036265-A1 | CHIMERIC TIM RECEPTORS AND USES THEREOF | CERO THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| US-20110003812-A1 | Human Adam-10 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003812-A1 | Human Adam-10 Inhibitors | ADAM10, MMP20, ADAM9 | MMP1 13/4885MMP9 12/4885MMP3 30/4885 |
| US-20260139061-A1 | TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRvIII CHIMERIC ANTIGEN RECEPTOR | EGFR, ERBB2, HAVCR2 | MMP1 4654/4885MMP9 4010/4885MMP3 3401/4885 |
| US-12616733-B2 | XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions | XBP1, MCL1, CD81 | MMP1 3890/4885MMP9 4456/4885MMP3 3611/4885 |
| US-12595260-B2 | Stable heavy isotopes in amide functional groups and uses thereof | SLC10A1, SLC9A1, SLC10A6 | MMP1 918/4885MMP9 1779/4885MMP3 1961/4885 |
| US-20260077015-A1 | CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF | CD47, TNFSF10, CD2 | MMP1 4152/4885MMP9 3328/4885MMP3 1633/4885 |
| US-12559562-B2 | Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor | EGFR, IGSF11, IGLV6-57 | MMP1 4693/4885MMP9 4726/4885MMP3 4078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.